

# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/078,241	02/20/2002	Patrice Duvert	022650-621	5583
7.	590 08/08/2003			
Mary Katherine Baumeister			EXAMINER	
BURNS, DOANE, SWECKER & MATHIS, L.L.P. P.O. Box 1404		PRYOR, ALTON NATHANIEL		
Alexandria, VA	Alexandria, VA 22313-1404		ART UNIT	PAPER NUMBER
			1616	$\mathcal{Q}$
			DATE MAILED: 08/08/2003	

Please find below and/or attached an Office communication concerning this application or proceeding.

<del></del>		Application No.	Applicant(s)
Office Action Summary		10/078,241	DUVERT, PATRICE
		Examiner	Art Unit
		Alton N. Pryor	1616
Period for	- The MAILING DATE of this communication app r Reply	pears on the cov r sheet	with the correspondence address
THE N - Extens after S - If the p - If NO p - Failure - Any re	DRTENED STATUTORY PERIOD FOR REPLINALING DATE OF THIS COMMUNICATION. Sions of time may be available under the provisions of 37 CFR 1.1 (SIX (6) MONTHS from the mailing date of this communication. Deriod for reply specified above is less than thirty (30) days, a replination for reply is specified above, the maximum statutory period to reply within the set or extended period for reply will, by statute the ply received by the Office later than three months after the mailing at patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may by within the statutory minimum of the will apply and will expire SIX (6) Mea, cause the application to become	a reply be timely filed  nirty (30) days will be considered timely.  DNTHS from the mailing date of this communication.  ABANDONED (35 U.S.C. § 133).
1) 🗌	Responsive to communication(s) filed on	<u> </u>	
2a) <u></u> □	This action is <b>FINAL</b> . 2b)⊠ Th	nis action is non-final.	
3)□ Dispositio	Since this application is in condition for allow closed in accordance with the practice under on of Claims		
4) 🗌 (	Claim(s) $1-26$ is/are pending in the application	n. ·	
4	a) Of the above claim(s) is/are withdra	wn from consideration.	
5) 🗌 🦸	Claim(s) is/are allowed.		
6)🛛	Claim(s) <u>1-26</u> is/are rejected.		
7) 🗌 🤚	Claim(s) is/are objected to.		
8) 🗌 (	Claim(s) are subject to restriction and/o	or election requirement.	
Application	on Papers	·	·
9)[] T	he specification is objected to by the Examine	er.	
10)∐ T	he drawing(s) filed on is/are: a)□ acce	pted or b) objected to by	the Examiner.
	Applicant may not request that any objection to the	e drawing(s) be held in abo	yance. See 37 CFR 1.85(a).
11)□ T	he proposed drawing correction filed on	_ is: a)□ approved b)□	disapproved by the Examiner.
	If approved, corrected drawings are required in re	ply to this Office action.	
12)∏ T	he oath or declaration is objected to by the Ex	kaminer.	
Priority u	nder 35 U.S.C. §§ 119 and 120		
13) 🗌 📝	Acknowledgment is made of a claim for foreig	n priority under 35 U.S.C	. § 119(a)-(d) or (f).
a)[	☐ All b) ☐ Some * c) ☐ None of:		
•	<ol> <li>Certified copies of the priority document</li> </ol>	s have been received.	
:	2. Certified copies of the priority document	s have been received in	Application No
	3. Copies of the certified copies of the prio application from the International Bu	reau (PCT Rule 17.2(a))	
	ee the attached detailed Office action for a list	•	
·	cknowledgment is made of a claim for domest		
15) 🗌 A	The translation of the foreign language procknowledgment is made of a claim for domest		
ttachment(			
2) 🔲 Notice	of References Cited (PTO-892) of Draftsperson's Patent Drawing Review (PTO-948) ation Disclosure Statement(s) (PTO-1449) Paper No(s) <u>2</u>	5) Notice	w Summary (PTO-413) Paper No(s)  of Informal Patent Application (PTO-152) .
. Patent and Tra		tion Summary	Part of Paper No. 4

Application/Control Number: 10/078,241

Art Unit: 1616

#### **DETAILED ACTION**

## Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:
The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 11-26 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for treating a fungi, does not reasonably provide enablement for preventing or curing fungi on plants. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make / use the invention commensurate in scope with these claims. The asserted utility is not believable on its face. It is not known how a method wherein a composition is claimed can be administered to prevent or cure fungal disease. The state of the art is what prior art knows about the invention. There is no known art wherein a certain composition is administered to successfully prevent or cure fungal growth on plants. The level of ordinary skill in the art is high but only in the art of treating said fungal growth. The predictability or lack thereof in the art refers to the ability of one skilled in the art to extrapolate the disclosed or known results to the claimed invention. The lower the predictability, the higher the direction and guidance that must be provided by the applicant. In the instant invention the predictability is very low and consequently,

Art Unit: 1616

the need for the higher levels of direction and guidance by the applicant. However, the amount of direction and guidance provided by the applicant is limited to treatment. There is no evidence in the specification that established correlation between the experiment and the claimed utility. The quantity of experimentation required to use the method as claimed in the instant invention, based on applicant's disclosure would be undue because, one of ordinary skill in the art would have performed significant amount of experiments.

### Claim Rejections - 35 USC § 102

(e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent.

The changes made to 35 U.S.C. 102(e) by the American Inventors Protection Act of 1999 (AIPA) and the Intellectual Property and High Technology Technical Amendments Act of 2002 do not apply when the reference is a U.S. patent resulting directly or indirectly from an international application filed before November 29, 2000. Therefore, the prior art date of the reference is determined under 35 U.S.C. 102(e) prior to the amendment by the AIPA (pre-AIPA 35 U.S.C. 102(e)).

Claims 1-20,23,24 are rejected under 35 U.S.C. 102(e) as being anticipated by Oguri (US 6518304; 2/11/03. Oguri teaches a fungicidal composition comprising 5 parts formula Ia (BAS 490F) plus 5 parts iprodione (1:1). Oguri teaches a fungicidal composition comprising 5 part formula Ie (SSF-129) and 5 part iprodione (1:1). See column 8 Formulation Example 8. Oguri teaches a fungicidal composition comprising 1 parts formula Ia (BAS 490F) plus 5 parts iprodione (0.2). Oguri teaches a fungicidal

Application/Control Number: 10/078,241

Art Unit: 1616

composition comprising 1 part formula le (SSF-129) and 5 part iprodione (0.2). See column 8 Formulation Example 7. Oguri teaches that the fungicidal composition can be present in a liquid or solid carrier along with a surfactant (surface active agent). See column 6 lines 43-51. Oguri teaches that the composition is applied to plants to control fungal growth at a rate of 0.001 to 1000 g / are. See column 7 lines 32-43.

#### Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 1-26 are rejected under 35 U.S.C. 103(a) as being unpatentable over Latrose (WO 9603044; 2/8/96), the US equivalent is USPN 5,906,986. Latrose teaches a fungicidal composition comprising a 2-imidazoline-5-one compound plus at least one additional fungicide. The additional fungicides include the instant iprodone (compound B), BAS 490F (compound A), and SSF 129 (compound A). Latrose teaches that the fungicidal composition can be present in a liquid or solid carrier along with a surface active agent. Latrose teaches that the composition is applied to plants to control fungal growth at a rate of 10 to 5000 g/ha. See WO' 044 abstract. See US '986 abstract, column 2 lines 2, 11-16, column 7 lines 55-65. Latrose differs from the prior art in that Latrose does not exemplify an invention comprising iprodone and BAS 490F or iprodone and SSF 129. Latrose also does not teach the instant ratios and application rates of ingredients. Because Latrose teaches that the additional compounds included

Application/Control Number: 10/078,241

Art Unit: 1616

in the composition is at least one of iprodone, SSF-129, and BAS-490F, it would have been obvious to one having ordinary skill in the art to develop an invention comprising iprodone plus SSF-129 or iprodone plus BAS-490F or iprodone plus SSF0-129 plus BAS-490F. One would have been motivated to do this because Latrose suggests the combination. With respect to the instant ratios of ingredients, one having ordinary skill in the art would have been expected to determine the optimum ratios through routine experimentation. One would have been motivated to do this in order to enhance the effectiveness of the invention at controlling fungal growth on plants. With respect to the application rates the prior art range (10-5000 g/ha of composition) overlaps the instant application rate range (150-7000 g/ha of composition). It is very possible the optimum application rate of the composition would have fallen at a point where the two (prior art and instant application) application rate ranges overlap.

#### Telephonic Inquiry

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Alton N. Pryor whose telephone number is 703 308-4691. The examiner can normally be reached on 8:00 a.m. - 4:30 p.m..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Thurman Page can be reached on 703-308-2927. The fax phone numbers for the organization where this application or proceeding is assigned are 703-305-3592 for regular communications and 703-305-3592 for After Final communications.